These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 37034617)
1. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species. Srinivasan S; Yee NA; Zakharian M; Alečković M; Mahmoodi A; Nguyen TH; Mejía Oneto JM bioRxiv; 2023 Mar; ():. PubMed ID: 37034617 [TBL] [Abstract][Full Text] [Related]
2. Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation. Wu K; Yee NA; Srinivasan S; Mahmoodi A; Zakharian M; Mejia Oneto JM; Royzen M Chem Sci; 2021 Jan; 12(4):1259-1271. PubMed ID: 34163888 [TBL] [Abstract][Full Text] [Related]
3. SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions. Srinivasan S; Yee NA; Wu K; Zakharian M; Mahmoodi A; Royzen M; Oneto JMM Adv Ther (Weinh); 2021 Mar; 4(3):. PubMed ID: 33869738 [TBL] [Abstract][Full Text] [Related]
4. Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents. McFarland JM; Alečković M; Coricor G; Srinivasan S; Tso M; Lee J; Nguyen TH; Mejía Oneto JM ACS Cent Sci; 2023 Jul; 9(7):1400-1408. PubMed ID: 37521794 [TBL] [Abstract][Full Text] [Related]
5. On-Demand Drug Release from Click-Refillable Drug Depots. Palvai S; Moody CT; Pandit S; Brudno Y Mol Pharm; 2021 Oct; 18(10):3920-3925. PubMed ID: 34494844 [TBL] [Abstract][Full Text] [Related]
6. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Cunningham C; Nemunaitis J Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Lopes de Menezes DE; Mayer LD Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538 [TBL] [Abstract][Full Text] [Related]
12. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719 [TBL] [Abstract][Full Text] [Related]
13. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760 [TBL] [Abstract][Full Text] [Related]
14. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. Siu L; Brody J; Gupta S; Marabelle A; Jimeno A; Munster P; Grilley-Olson J; Rook AH; Hollebecque A; Wong RKS; Welsh JW; Wu Y; Morehouse C; Hamid O; Walcott F; Cooper ZA; Kumar R; Ferté C; Hong DS J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037117 [TBL] [Abstract][Full Text] [Related]
15. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373 [TBL] [Abstract][Full Text] [Related]
16. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. Davis EJ; Martin-Liberal J; Kristeleit R; Cho DC; Blagden SP; Berthold D; Cardin DB; Vieito M; Miller RE; Hari Dass P; Orcurto A; Spencer K; Janik JE; Clark J; Condamine T; Pulini J; Chen X; Mehnert JM J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316061 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. Zaleskis G; Garberytė S; Pavliukevičienė B; Valinčius G; Characiejus D; Mauricas M; Kraśko JA; Žilionytė K; Žvirblė M; Pašukonienė V J Cancer; 2020; 11(22):6497-6506. PubMed ID: 33046971 [No Abstract] [Full Text] [Related]
18. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648 [TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Wong HL; Rauth AM; Bendayan R; Wu XY Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]